BioNTech
BioNTech is a Germany-based biotechnology company that specializes in developing innovative immunotherapies for cancer and other serious diseases, as well as vaccines for infectious diseases, including COVID-19. The company’s oncology pipeline includes a range of drug classes, such as mRNA-based drugs that encode antigens and neoantigens, cell therapies, bispecific antibodies, and antibody-drug conjugates. BioNTech has established partnerships with several major pharmaceutical companies, enhancing its research and development capabilities. Its COVID-19 vaccine, Comirnaty, represents its first commercialized product, demonstrating the company's commitment to addressing urgent health challenges through advanced therapeutic approaches.
Top Stages
10 past transactions
Biotheus
Acquisition in 2024
Biotheus Inc. is a biotechnology company based in Zhuhai, China, founded in 2018. The company specializes in the development and commercialization of innovative biologics, focusing primarily on monoclonal antibodies, recombinant proteins, and peptide biopharmaceuticals. Biotheus is dedicated to addressing malignant tumors and autoimmune diseases by researching and developing next-generation multispecific antibodies. The company explores the mechanisms of regulatory T cells and innate immunity to create antibody-based therapeutics that enhance immune therapy and provide effective treatments for cancer and metabolic disorders.
Crescendo Biologics
Venture Round in 2023
Crescendo Biologics develops innovative antibody therapeutics using its proprietary platforms. The company focuses on generating high-affinity, human VH antibody fragments for oncology and other indications. Its technology is based on a transgenic mouse platform that enables the creation of fully human VHH domain building blocks.
InstaDeep
Acquisition in 2023
Founded in London in 2015, InstaDeep develops AI-based decision-making systems for enterprises. Its platform offers advanced pattern recognition, GPU-accelerated insights, self-learning systems, machine learning, and predictive analytics to optimize decisions across manufacturing, logistics, mobility, and energy sectors.
GREENFORCE
Venture Round in 2022
Greenforce specializes in the development and sale of plant-based food products, focusing on sustainable meat and milk alternatives. The company offers a range of 100% vegan items made from high-quality raw materials sourced from reputable suppliers, ensuring transparency throughout its value chain. Greenforce aims to provide cruelty-free vegetable-based meat substitutes, particularly in easy-to-mix powder form, catering to the needs of vegan customers. By delivering high-protein and environmentally friendly alternatives, the company addresses the growing demand for sustainable food sources, positioning itself to help secure protein supplies for future generations.
Ryvu
Post in 2022
Ryvu is a biopharmaceutical company developing small-molecule therapies that address the clinical limitations of current treatments in oncology.
MediGene
Post in 2022
MediGene AG is a biotechnology company focused on immuno-oncology, specializing in the development of differentiated T Cell Receptor engineered T cell (TCR-T) therapies for treating various solid tumor indications with high unmet medical needs. Its primary operating segments are Immunotherapies and Other products, with Immunotherapies comprising T-cell receptor-based adoptive T-cell therapy and DC vaccines. MediGene operates globally, with significant revenue generated from its operations in Germany.
InstaDeep
Series B in 2022
Founded in London in 2015, InstaDeep develops AI-based decision-making systems for enterprises. Its platform offers advanced pattern recognition, GPU-accelerated insights, self-learning systems, machine learning, and predictive analytics to optimize decisions across manufacturing, logistics, mobility, and energy sectors.
PhagoMed Biopharma
Acquisition in 2021
PhagoMed Biopharma GmbH, established in 2017 and headquartered in Vienna, Austria, specializes in developing virus-based therapies targeting bacterial infections. The company's core focus is the creation of human therapeutic applications using phages (viruses that infect bacteria) and phage-derived proteins to combat urinary tract infections and bacterial vaginosis, aiming to provide alternative treatments when antibiotics are ineffective or inappropriate.
Kite - TCR therapy
Acquisition in 2021
TCR therapy is a type of cellular immunotherapy designed to redirect the patient’s immune system in order to recognize and target tumors.
Neon Therapeutics
Acquisition in 2020
Neon Therapeutics is a clinical-stage biopharmaceutical company specializing in neoantigen-targeted therapies aimed at revolutionizing cancer treatment. By harnessing the immune system's ability to recognize and attack neoantigens, the company seeks to develop innovative therapies that improve patient outcomes. Its product pipeline includes NEO-PV-01, NEO-PTC-01, and NEO-SV-01, which are designed to enhance the immune response against tumors. Through its focused research and development efforts, Neon Therapeutics is committed to advancing the field of immuno-oncology and providing new options for cancer patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.